Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, announces it will be exhibiting at the American Association for Cancer Research (AACR) Annual Meeting, 2024, held in San Diego, California, at the San Diego Convention Center from April 5 to 10.
Senhwa Biosciences, Inc. announced that Taiwan Food and Drug Administration has approved its Phase II IND application of Silmitasertib to treat patients with community-acquired pneumonia caused by.
/PRNewswire/ Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and.